Results 51 to 60 of about 77,584 (306)

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases [PDF]

Chonnam Medical Journal, 2016
Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states.
Yoon, Somy, Eom, Gwang Hyeon
openaire   +2 more sources

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma [PDF]

, 2008
The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid (VPA) are limited and concentrations required for exerting anti ...
Atmaca, Akin, Batran, Salah-Eddin al-, Blaheta, Roman A., Hudak, Lukasz, Jonas, Dietger, Jüngel, Eva, Soldato, Piero Del, Sparatore, Anna, Wedel, Steffen Alexander   +8 more
core   +1 more source

HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal [PDF]

, 2018
Peritoneal fibrosis is a pathological alteration of the peritoneal membrane occurring in a variety of conditions including peritoneal dialysis (PD), post-surgery adhesions and peritoneal metastases.
Battistelli, Cecilia, Bordoni, Veronica, DE TURRIS, Valeria, Domenici, Alessandro, Mai, Antonello, Manzione, Andrea, Mene', Paolo, Moioli, Alessandra, Noce, Valeria, Palladino, Marco, Rossi, Lucia, Strippoli, Raffaele, Tripodi, Marco, Valente, Sergio, Zwergel, Clemens   +14 more
core   +1 more source

Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer

Epigenetics, 2020
Histone deacetylases (HDACs) have been linked to a variety of cancers, and HDAC inhibitors (HDACi) are a promising class of drugs that have demonstrated anti-cancer effects.
Yingyan Han, Zhi Wang, Shujuan Sun, Zeyu Zhang, Jia Liu, Xin Jin, Peng Wu, Teng Ji, Wencheng Ding, Beibei Wang, Qinglei Gao   +10 more
doaj   +1 more source

Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors [PDF]

, 2017
Heat shock protein 90 (HSP90) regulates multiple signalling pathways critical for tumour growth. As such, HSP90 inhibitors have been shown to act as effective anticancer agents in preclinical studies but, for a number of reasons, the same effect has not ...
Baker, Brough, Butler, Cercek, Chambers, Chen, Dickson, Eccles, Gaspar, George, Greer, Guo, Heath, Holmes, Jhaveri, Johnson, Kim, Kovacs, Kramer, Liu, Maloney, McCollum, McCollum, Page, Peserico, Price, Rae, Ramalingam, Rao, Rocha Dias, Ronnen, Ross, Sato, Scroggins, Sellappan, Sharp, Skehan, Smith, Solit, Tatokoro, Trepel, Wang, Wang, Wardley, Wei, Whitesell, Whitesell, Xu, Yang, Yong, Younes, Zhang, Zhang, Zupkovitz   +53 more
core   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Epigenetic Regulation of Matrix Metalloproteinase-1 and -3 Expression in Mycobacterium tuberculosis Infection. [PDF]

, 2017
In pulmonary tuberculosis (TB), the inflammatory immune response against Mycobacterium tuberculosis (Mtb) is associated with tissue destruction and cavitation, which drives disease transmission, chronic lung disease, and mortality.
Alland, Aung, Azad, Bannister, Barchowsky, Bell, Bird, Brilha, Chen, Chernov, Choudhary, Culley, de Ruijter, Dobaczewski, Elkington, Feng, Goldberg, Green, Gregoire, Gregoretti, Horiuchi, Jaspers, Khan, Kim, Kleinsteuber, Kubler, Kumar, Lee, Loffek, Lu, Maciejewska-Rodrigues, Majeed, McErlean, McGarry Houghton, Michael, Mittelstadt, Mortaz, Moser, Nasu, Omanakuttan, Ong, Ong, Roger, Shahbazian, Shammari, Singh, Swamy, Tezera, Thuong, Wallis, Wang, Wang, Wolffe   +52 more
core   +2 more sources

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, EarlyView.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

Hepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu, Bingqing Xu, Xiaodong Wang, Wen‐Hua Wan, Jinying Lu, Deyuan Kong, Yu Jin, Wenhua You, Hua Sun, Xiaoxin Mu, Dongju Feng, Yun Chen   +11 more
wiley   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source